Natera says Signatera-negative immunotherapy patients had 93.2% 36-month survival vs 77.9%

Natera said Signatera-negative immunotherapy patients had 93.2% 36-month survival versus 77.9%, with no significant difference after stopping treatment.

Detected & updated continuously · Source: Nebula